Abstract
Objective: This review study examines mucormycosis treatment challenges, gaps in medicines, and COVID-19-related effects. This paper examines diagnostic and drug development advances while addressing safety and specificity. Methods: This review study searches PubMed, Web Science, and Scopus for relevant material. Keywords associated with mucormycosis, therapy, diagnosis, medication advancement, and COVID- 19 are used to identify pertinent articles. Data extraction summarizes therapeutic obstacles, diagnostic advances, and innovative drug options. Results: This review article covers mucormycosis therapy, diagnostics, and drug development. It reveals limitations in present medicines, such as selectivity, safety, and resistance mechanisms. Diagnostic advances and mucormycosis in COVID-19 have also been explored. Conclusion: This review emphasizes the need for more secure, specific mucormycosis therapies. It discusses therapy obstacles, diagnostic advances, and new drug techniques. Overall, this research emphasizes improving mucormycosis therapy to enhance patient outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
